Successful treatment with tacrolimus in a case of refractory dermatomyositis

Internal Medicine

Volumn 44, Issue 11, 2005, Pages 1197-1199

  Mitsui, Takao ^a   Kuroda, Yukiko ^a   Kunishige, Makoto ^a   Matsumoto, Toshio ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Ileus; IVIG; Plasma exchange; Refractory; Rhabdomyolysis

Indexed keywords

IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; TACROLIMUS; DERMATOLOGICAL AGENT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

ABNORMAL URINE COMPOSITION; ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; DERMATOMYOSITIS; DRUG BLOOD LEVEL; DYSPHAGIA; ELECTROMYOGRAM; ERYTHEMA; EYELID EDEMA; FACE MUSCLE; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY FUNCTION; LIMB WEAKNESS; MALE; MUSCLE BIOPSY; NECK MUSCLE; NEUROLOGIC EXAMINATION; PARALYTIC ILEUS; PLASMAPHERESIS; RESPIRATORY TRACT DISEASE; RHABDOMYOLYSIS; WEAKNESS; DRUG COMBINATION; DRUG RESISTANCE; FOLLOW UP; TREATMENT OUTCOME;

ADULT; DERMATOLOGIC AGENTS; DERMATOMYOSITIS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; TACROLIMUS; TREATMENT OUTCOME;

EID: 33644848425     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.44.1197     Document Type: Article

References (11)

1. Mastaglia FL, Garlepp MJ, Phillips BA, Zilko PJ. Inflammatory myopathies: clinical, diagnostic and therapeutic aspects. Muscle Nerve 27: 407-425, 2003.
2. Fukunaga E, Kunishige M, Mitsui T, et al. Severe dermatomyositis with rhabdomyolysis and paralytic ileus: a case successfully treated with plasmapheresis and intravenous immunoglobulin. Eur J Neurol 9: 697-698, 2002.
3. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329: 1993-2000, 1993.
4. Spiera R, Kagen L. Extramuscular manifestations in idiopathic inflammatory myopathies. Curr Opin Rheumatol 10: 556-561, 1998.
5. Marie I, Kerleau JM, Ducrotte P, et al. Intravenous immunoglobulins and octreotide as treatment of intestinal pseudo-obstruction revealing a recurrence of polymyositis. Rheumatology (Oxford) 40: 1072-1073, 2001.
6. Bierer BE, Holländer G, Fruman D, Burakoff SJ. Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology. Curr Opin Immunol 5: 763-773, 1993.
7. Allison AC. Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology 47: 63-83, 2000.
8. Utsugisawa K, Nagane Y, Yonezawa H, Obara D, Kondoh R, Tohgi H. Effects of FK506 on myasthenia gravis patients with high interleukin-2 productivity in peripheral blood mononuclear cells. Muscle Nerve 27: 245-248, 2003.
9. Modesto C, Boronat M, Marsal S, Arnal-Guimera C. FK-506 in the treatment of unresponsive juvenile dermatomyositis. Ann Rheum Dis 59: 728, 2000.
10. Yoshimasu T, Ohtani T, Sakamoto T, Oshima A, Furukawa F. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol 12: 50-52, 2002.
11. Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet. 353: 1762-1763, 1999.